Patents by Inventor Youichi KAWAKITA
Youichi KAWAKITA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11897879Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.Type: GrantFiled: November 17, 2021Date of Patent: February 13, 2024Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Takaharu Hirayama, Yoshiteru Ito, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
-
Patent number: 11390634Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].Type: GrantFiled: December 22, 2020Date of Patent: July 19, 2022Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Youichi Kawakita, Takuto Kojima, Noriyuki Nii, Yoshiteru Ito, Nobuki Sakauchi, Hiroshi Banno, Xin Liu, Koji Ono, Keisuke Imamura, Shinichi Imamura
-
Publication number: 20220089595Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.Type: ApplicationFiled: November 17, 2021Publication date: March 24, 2022Inventors: Takaharu Hirayama, Yoshiteru Ito, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
-
Publication number: 20220048916Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.Type: ApplicationFiled: November 27, 2019Publication date: February 17, 2022Applicant: Takeda Pharmaceutical Company LimitedInventors: Takaharu Hirayama, Yoshiteru Ito, Hiroshi Banno, Hidekazu Tokuhara, Toshio Tanaka, Yasuyoshi Arikawa, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
-
Patent number: 11230545Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.Type: GrantFiled: July 2, 2021Date of Patent: January 25, 2022Assignee: Takeda Pharmaceutical Company LimitedInventors: Takaharu Hirayama, Yoshiteru Ito, Hiroshi Banno, Hidekazu Tokuhara, Toshio Tanaka, Yasuyoshi Arikawa, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
-
Publication number: 20210332045Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.Type: ApplicationFiled: July 2, 2021Publication date: October 28, 2021Inventors: Takaharu Hirayama, Yoshiteru Ito, Hiroshi Banno, Hidekazu Tokuhara, Toshio Tanaka, Yasuyoshi Arikawa, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
-
Publication number: 20210115067Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].Type: ApplicationFiled: December 22, 2020Publication date: April 22, 2021Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Youichi KAWAKITA, Takuto KOJIMA, Noriyuki NII, Yoshiteru ITO, Nobuki SAKAUCHI, Hiroshi BANNO, Xin LIU, Koji ONO, Keisuke IMAMURA, Shinichi IMAMURA
-
Patent number: 10981934Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].Type: GrantFiled: October 25, 2019Date of Patent: April 20, 2021Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Youichi Kawakita, Takuto Kojima, Noriyuki Nii, Yoshiteru Ito, Nobuki Sakauchi, Hiroshi Banno, Xin Liu, Koji Ono, Keisuke Imamura, Shinichi Imamura
-
Publication number: 20200140462Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].Type: ApplicationFiled: October 25, 2019Publication date: May 7, 2020Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Youichi KAWAKITA, Takuto KOJIMA, Noriyuki NII, Yoshiteru ITO, Nobuki SAKAUCHI, Hiroshi BANNO, Xin LIU, Koji ONO, Keisuke IMAMURA, Shinichi IMAMURA
-
Patent number: 10577382Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein].Type: GrantFiled: April 27, 2017Date of Patent: March 3, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Youichi Kawakita, Takuto Kojima, Noriyuki Nii, Yoshiteru Ito, Nobuki Sakauchi, Hiroshi Banno, Xin Liu, Koji Ono, Keisuke Imamura, Shinichi Imamura
-
Publication number: 20190106437Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].Type: ApplicationFiled: April 27, 2017Publication date: April 11, 2019Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Youichi KAWAKITA, Takuto KOJIMA, Noriyuki NII, Yoshiteru ITO, Nobuki SAKAUCHI, Hiroshi BANNO, Xin LIU, Koji ONO, Keisuke IMAMURA, Shinichi IMAMURA
-
Publication number: 20100216788Abstract: The present invention provides a compound represented by the formula: wherein R1a is a hydrogen atom, R2a is a C1-6 alkyl group substituted by a group represented by —NR6a—CO—(CH2)n—SO2— optionally halogenated C1-4 alkyl wherein n is an integer of 1 to 4, R6a is a hydrogen atom or a C1-4 alkyl group, and —(CH2)n— is optionally substituted by C1-4 alkyl, R3a is a hydrogen atom or a C1-6 alkyl group, R4a is a halogen atom or a C1-6 alkyl group, R5a is a halogen atom or a C1-6 alkyl group, and Xa is a hydrogen atom or a halogen atom, or a salt thereof. The compound of the present invention has a superior tyrosine kinase inhibitory action, is highly safe, and is sufficiently satisfactory as a pharmaceutical product.Type: ApplicationFiled: December 1, 2006Publication date: August 26, 2010Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Tomoyasu Ishikawa, Kazuhiro Miwa, Masaki Seto, Hiroshi Banno, Youichi Kawakita
-
Publication number: 20100004238Abstract: The present invention provides a fused heterocyclic compound having a tyrosine kinase inhibitory action, which is represented by the formula: wherein R1 is a hydrogen atom, a halogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom; R2 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom, or R1 and R2, or R2 and R3 are optionally bonded to each other to form an optionally substituted ring structure; R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 is optionally bonded to the carbon atom on ring A to form an optionally substituted ring structure; ring A is an optionally substituted benzene ring; and ring B is (i) an optionally substituted fused ring, or (ii) a pyridine ring having optionally substituted carbamoyl (the pyridine ring is optionally further substituted).Type: ApplicationFiled: December 11, 2007Publication date: January 7, 2010Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Tomoyasu Ishikawa, Hiroshi Banno, Youichi Kawakita, Tomohiro Ohashi, Osamu Kurasawa
-
Publication number: 20090233937Abstract: The present invention provides a fused heterocyclic compound having a tyrosine kinase inhibitory action, which is represented by the formula: wherein ring A is an optionally substituted benzene ring; ring B is an optionally substituted benzoisothiazole ring; R1 is a hydrogen atom, a halogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom; R2 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom; R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group; or R1 and R2, or R2 and R3 are optionally bonded to each other to form an optionally substituted ring structure; or R3 is optionally bonded to the carbon atom on ring A to form an optionally substituted ring structure; or a salt thereof.Type: ApplicationFiled: March 11, 2009Publication date: September 17, 2009Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Tomoyasu ISHIKAWA, Youichi KAWAKITA
-
Publication number: 20080269238Abstract: The present invention provides a compound represented by the following Formula: wherein A is an aryl group or a heteroaryl group, each of which may be substituted; R1 is a group which is bonded through carbon; R2 is hydrogen or an aliphatic hydrocarbon group; and X is —NR3—, —O—, —S—, —SO—, —SO2—, or —CHR3— (wherein R3 is hydrogen or an aliphatic hydrocarbon group), or a salt thereof, or a prodrug thereof, which has growth factor receptor tyrosine kinase inhibitory activity and low toxicity, and is useful for prevention and treatment of cancer, and thus can be sufficiently used as a medicine.Type: ApplicationFiled: March 31, 2005Publication date: October 30, 2008Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshihiro Sugihara, Youichi Kawakita